HK1220912A1 - 減少身體脂肪的方法和成份 - Google Patents
減少身體脂肪的方法和成份Info
- Publication number
- HK1220912A1 HK1220912A1 HK16109109.1A HK16109109A HK1220912A1 HK 1220912 A1 HK1220912 A1 HK 1220912A1 HK 16109109 A HK16109109 A HK 16109109A HK 1220912 A1 HK1220912 A1 HK 1220912A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- compositions
- methods
- body fat
- reducing body
- reducing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
- A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being unsaturated and containing rings other than six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/732—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids of unsaturated hydroxy carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/20—Oxygen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161434337P | 2011-01-19 | 2011-01-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1220912A1 true HK1220912A1 (zh) | 2017-05-19 |
Family
ID=46516342
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK14104208.4A HK1190936A1 (zh) | 2011-01-19 | 2014-05-02 | 治療代謝綜合徵的方法和配方 |
HK16109109.1A HK1220912A1 (zh) | 2011-01-19 | 2014-05-02 | 減少身體脂肪的方法和成份 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK14104208.4A HK1190936A1 (zh) | 2011-01-19 | 2014-05-02 | 治療代謝綜合徵的方法和配方 |
Country Status (7)
Country | Link |
---|---|
US (3) | US9089579B2 (zh) |
EP (3) | EP3378480A1 (zh) |
JP (2) | JP5778781B2 (zh) |
CA (2) | CA2824317C (zh) |
ES (2) | ES2687494T3 (zh) |
HK (2) | HK1190936A1 (zh) |
WO (1) | WO2012099942A2 (zh) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2006270165B2 (en) | 2005-07-14 | 2010-03-11 | Neothetics, Inc. | Sustained release enhanced lipolytic formulation for regional adipose tissue treatment |
WO2007111806A2 (en) | 2006-03-23 | 2007-10-04 | Massachusetts Eye And Ear Infirmary | Cyclopentane heptanoic acid compounds for reducing body fat |
US9132084B2 (en) | 2009-05-27 | 2015-09-15 | Neothetics, Inc. | Methods for administration and formulations for the treatment of regional adipose tissue |
SG10201805840WA (en) | 2009-11-09 | 2018-08-30 | Allergan Inc | Compositions and methods for stimulating hair growth |
ES2687494T3 (es) | 2011-01-19 | 2018-10-25 | Topokine Therapeutics, Inc. | Métodos y composiciones para reducir la grasa corporal |
US8426471B1 (en) | 2011-12-19 | 2013-04-23 | Topokine Therapeutics, Inc. | Methods and compositions for reducing body fat and adipocytes |
GB2507341A (en) * | 2012-10-29 | 2014-04-30 | Peter Kenny | Fat loss composition comprising a prostaglandin F2 alpha analogue and a fragment of amino acids 176-191 of human growth hormone |
WO2014081941A1 (en) | 2012-11-21 | 2014-05-30 | Topokine Therapeutics, Inc. | Methods and compositions for locally increasing body fat |
AU2014228307A1 (en) * | 2013-03-15 | 2015-09-10 | Allergan, Inc. | Bimatoprost for enhancement of leptin production |
NO2753788T3 (zh) | 2013-05-10 | 2018-06-16 | ||
US9820993B2 (en) | 2013-05-15 | 2017-11-21 | Topokine Therapeutics, Inc. | Methods and compositions for topical delivery of prostaglandins to subcutaneous fat |
WO2015200425A1 (en) * | 2014-06-27 | 2015-12-30 | Topokine Therapeutics, Inc. | Topical dosage regimen |
KR20180058758A (ko) | 2015-09-22 | 2018-06-01 | 그레이버그 비젼, 인크. | 안구 장애의 치료를 위한 화합물 및 조성물 |
US10285998B1 (en) | 2018-04-04 | 2019-05-14 | The Menopause Method, Inc. | Composition and method to aid in hormone replacement therapy |
US10835502B2 (en) | 2018-10-16 | 2020-11-17 | Polithera, Inc. | Alcohol-based compositions and uses thereof |
WO2023065203A1 (en) * | 2021-10-21 | 2023-04-27 | Givaudan Sa | Organic compounds |
Family Cites Families (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
US4599353A (en) | 1982-05-03 | 1986-07-08 | The Trustees Of Columbia University In The City Of New York | Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
CA1283827C (en) | 1986-12-18 | 1991-05-07 | Giorgio Cirelli | Appliance for injection of liquid formulations |
GB8704027D0 (en) | 1987-02-20 | 1987-03-25 | Owen Mumford Ltd | Syringe needle combination |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US4940460A (en) | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
EP0302147A1 (en) | 1987-08-03 | 1989-02-08 | The Procter & Gamble Company | Topical tanning compositions |
US5339163A (en) | 1988-03-16 | 1994-08-16 | Canon Kabushiki Kaisha | Automatic exposure control device using plural image plane detection areas |
US5296504A (en) | 1988-09-06 | 1994-03-22 | Kabi Pharmacia | Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension |
ES2186670T3 (es) | 1988-09-06 | 2003-05-16 | Pharmacia Ab | Derivados de prostaglandina para el tratamiento del glaucoma o la hipertension ocular. |
FR2638359A1 (fr) | 1988-11-03 | 1990-05-04 | Tino Dalto | Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5011062A (en) | 1990-05-09 | 1991-04-30 | Delco Electronics Corporation | Ultrasonic welding mask |
US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
GB9118204D0 (en) | 1991-08-23 | 1991-10-09 | Weston Terence E | Needle-less injector |
SE9102652D0 (sv) | 1991-09-13 | 1991-09-13 | Kabi Pharmacia Ab | Injection needle arrangement |
US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US5972991A (en) | 1992-09-21 | 1999-10-26 | Allergan | Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents |
US5688819A (en) | 1992-09-21 | 1997-11-18 | Allergan | Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents |
US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
US5334144A (en) | 1992-10-30 | 1994-08-02 | Becton, Dickinson And Company | Single use disposable needleless injector |
US5510383A (en) | 1993-08-03 | 1996-04-23 | Alcon Laboratories, Inc. | Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension |
JPH07138258A (ja) | 1993-11-16 | 1995-05-30 | Taiho Yakuhin Kogyo Kk | チアゾリジンジオン誘導体又はその塩 |
WO1995024176A1 (en) | 1994-03-07 | 1995-09-14 | Bioject, Inc. | Ampule filling device |
US5466220A (en) | 1994-03-08 | 1995-11-14 | Bioject, Inc. | Drug vial mixing and transfer device |
US5631287A (en) | 1994-12-22 | 1997-05-20 | Alcon Laboratories, Inc. | Storage-stable prostaglandin compositions |
US5902726A (en) * | 1994-12-23 | 1999-05-11 | Glaxo Wellcome Inc. | Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma |
US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
US5893397A (en) | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
GB9607549D0 (en) | 1996-04-11 | 1996-06-12 | Weston Medical Ltd | Spring-powered dispensing device |
RU2157689C2 (ru) | 1996-07-24 | 2000-10-20 | Панацея Биотек Лтд. | Фармацевтические композиции терапевтического антивоспалительного и болеутоляющего средства для местного нанесения и способ их получения |
JP3480549B2 (ja) | 1996-12-26 | 2003-12-22 | 参天製薬株式会社 | ジフルオロプロスタグランジン誘導体およびその用途 |
ATE266397T1 (de) | 1997-02-04 | 2004-05-15 | Murray A Johnstone | Verfahren zur förderung des haarwuchses und entwicklung des haarsystems |
US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
US6646001B2 (en) | 1997-12-19 | 2003-11-11 | Alcon Manufacturing, Ltd. | Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension |
AU1709699A (en) | 1997-12-22 | 1999-07-12 | Alcon Laboratories, Inc. | 13-oxa prostaglandins for the treatment of glaucoma and ocular hypertension |
IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
US6235781B1 (en) | 1998-07-14 | 2001-05-22 | Alcon Laboratories, Inc. | Prostaglandin product |
CA2714081C (en) | 2000-02-10 | 2013-08-06 | Massachusetts Eye And Ear Infirmary | Methods and compositions for treating conditions of the eye |
US20020172693A1 (en) | 2000-03-31 | 2002-11-21 | Delong Michell Anthony | Compositions and methods for treating hair loss using non-naturally occurring prostaglandins |
ES2172415B2 (es) | 2000-07-28 | 2003-11-16 | Univ Madrid Complutense | Tratamiento del glaucoma y la hipertension ocular por medio de un analogo de la melatonina. |
AU2002338329B2 (en) | 2001-03-27 | 2006-09-07 | The Regents Of The University Of California | Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism |
GB0202159D0 (en) | 2002-01-30 | 2002-03-20 | Sensor Highway Ltd | OPtical time domain reflectometry |
IL147921A0 (en) | 2002-01-31 | 2002-08-14 | Abdulrazik Mohammad | A method for treating central nervous system disorders by ocular dosing |
US7351404B2 (en) | 2002-02-04 | 2008-04-01 | Allergan, Inc. | Method of enhancing hair growth |
US6864282B2 (en) * | 2002-08-05 | 2005-03-08 | Allergan, Inc. | 9,11-cycloendoperoxide pro-drugs of prostaglandin analogues for treatment of ocular hypertension and glaucoma |
US20040115234A1 (en) | 2002-09-24 | 2004-06-17 | Gewirtz Joan T. | Cosmetic composition |
US20050261641A1 (en) | 2002-09-26 | 2005-11-24 | Warchol Mark P | Method for ophthalmic administration of medicament |
DK1562604T3 (da) * | 2002-10-23 | 2012-04-02 | Sucampo Ag | Prostaglandinforbindelser til behandling af fedme |
US7074827B2 (en) | 2002-10-24 | 2006-07-11 | Sucampo Ag (Usa) Inc. | Method for treating ocular hypertension and glaucoma |
BRPI0408454A (pt) | 2003-03-21 | 2006-04-04 | Nexmed Holdings Inc | composição tópica, método de tratar a ejaculação precoce, e, uso da composição |
US6933289B2 (en) | 2003-07-01 | 2005-08-23 | Allergan, Inc. | Inhibition of irritating side effects associated with use of a topical ophthalmic medication |
US20050058614A1 (en) | 2003-09-15 | 2005-03-17 | Allergan, Inc. | Methods for the treatment of gray hair using cyclopentane(ene) heptan(en)oic acid amides |
US7070768B2 (en) | 2003-09-25 | 2006-07-04 | Allergan, Inc. | Method for imparting artificial tan to human skin |
US7799336B2 (en) * | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
US8722097B2 (en) | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
US20090093463A1 (en) * | 2004-11-02 | 2009-04-09 | Agouron Pharmaceuticals Inc. | Novel compounds of substituted and unsubtituted adamantyl amides |
DE602004017477D1 (de) | 2004-11-09 | 2008-12-11 | Novagali Pharma Sa | Öl-in-Wasser-Emulsion mit niedriger Konzentration des kationischen Mittels und positivem Zetapotential |
WO2006082588A2 (en) | 2005-02-07 | 2006-08-10 | Pharmalight Inc. | Method and device for ophthalmic administration of active pharmaceutical ingredients |
PL1864666T3 (pl) | 2005-03-31 | 2013-02-28 | Agc Inc | Czynnik ochronny dla komórki neuronalnej siatkówki zawierający jako składnik aktywny pochodną prostaglandyny F2 alfa |
US9393218B2 (en) | 2005-12-23 | 2016-07-19 | Epinamics Gmbh | Use of film-forming hair care polymers from the group of polyurethanes and pharmaceutical preparations and patches that contain these polymers |
WO2007111806A2 (en) | 2006-03-23 | 2007-10-04 | Massachusetts Eye And Ear Infirmary | Cyclopentane heptanoic acid compounds for reducing body fat |
WO2007123818A2 (en) * | 2006-04-18 | 2007-11-01 | Nitromed, Inc. | Organic nitric oxide enhancing salts of prostaglandins, compositions and methods of use |
RU2325912C1 (ru) | 2006-09-06 | 2008-06-10 | Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") | Фармацевтическая композиция противовоспалительного и антимикробного действия в форме мази на гидрофобной основе для лечения кожных заболеваний (варианты) |
US8796282B2 (en) | 2007-03-28 | 2014-08-05 | Case Western Reserve University | Method of treating dermatological disorders |
WO2008120249A1 (en) | 2007-03-30 | 2008-10-09 | Sifi S.P.A. | Pharmaceutical formulations based on apolar and polar lipids for ophthalmic use |
WO2010039535A1 (en) | 2008-09-23 | 2010-04-08 | Meta Cosmetics, Llc | Compositions and methods to treat epithelial-related conditions |
US20100104654A1 (en) | 2008-10-27 | 2010-04-29 | Allergan, Inc. | Prostaglandin and prostamide drug delivery systems and intraocular therapeutic uses thereof |
US8722739B2 (en) * | 2008-10-29 | 2014-05-13 | Novaer Holdings, Inc. | Amino acid salts of prostaglandins |
CN101427993A (zh) | 2008-11-20 | 2009-05-13 | 沈阳万爱普利德医药科技有限公司 | ***素微乳凝胶制剂及其制备方法 |
EP2228058A1 (en) | 2009-03-04 | 2010-09-15 | Novagali Pharma S.A. | Anionic oil-in-water emulsion containing prostaglandins and uses thereof |
SG10201805840WA (en) | 2009-11-09 | 2018-08-30 | Allergan Inc | Compositions and methods for stimulating hair growth |
ES2711274T3 (es) | 2010-11-18 | 2019-04-30 | Steven Yoelin | Composiciones y métodos para el crecimiento del cabello |
ES2687494T3 (es) | 2011-01-19 | 2018-10-25 | Topokine Therapeutics, Inc. | Métodos y composiciones para reducir la grasa corporal |
BR112013020719B1 (pt) | 2011-02-14 | 2018-04-17 | Allergan, Inc. | Composições de derivados de bimatoprost tipo éster e métodos |
US8426471B1 (en) | 2011-12-19 | 2013-04-23 | Topokine Therapeutics, Inc. | Methods and compositions for reducing body fat and adipocytes |
US20150164765A1 (en) | 2012-05-17 | 2015-06-18 | Steven G. Yoelin | Compositions and methods for hair growth |
KR20140043562A (ko) | 2012-09-24 | 2014-04-10 | 한국콜마주식회사 | 무복계면 라타노프로스트 및 그 제조방법 |
WO2014081941A1 (en) | 2012-11-21 | 2014-05-30 | Topokine Therapeutics, Inc. | Methods and compositions for locally increasing body fat |
NO2753788T3 (zh) | 2013-05-10 | 2018-06-16 | ||
US9820993B2 (en) | 2013-05-15 | 2017-11-21 | Topokine Therapeutics, Inc. | Methods and compositions for topical delivery of prostaglandins to subcutaneous fat |
WO2015200425A1 (en) | 2014-06-27 | 2015-12-30 | Topokine Therapeutics, Inc. | Topical dosage regimen |
-
2012
- 2012-01-18 ES ES15180363.2T patent/ES2687494T3/es active Active
- 2012-01-18 JP JP2013550556A patent/JP5778781B2/ja not_active Expired - Fee Related
- 2012-01-18 EP EP18166647.0A patent/EP3378480A1/en not_active Withdrawn
- 2012-01-18 US US13/980,179 patent/US9089579B2/en active Active
- 2012-01-18 CA CA2824317A patent/CA2824317C/en not_active Expired - Fee Related
- 2012-01-18 WO PCT/US2012/021692 patent/WO2012099942A2/en active Application Filing
- 2012-01-18 CA CA2866067A patent/CA2866067C/en not_active Expired - Fee Related
- 2012-01-18 EP EP12736090.7A patent/EP2665481B1/en not_active Not-in-force
- 2012-01-18 ES ES12736090.7T patent/ES2579990T3/es active Active
- 2012-01-18 EP EP15180363.2A patent/EP2982373B1/en not_active Not-in-force
-
2014
- 2014-05-02 HK HK14104208.4A patent/HK1190936A1/zh not_active IP Right Cessation
- 2014-05-02 HK HK16109109.1A patent/HK1220912A1/zh not_active IP Right Cessation
- 2014-10-08 US US14/509,680 patent/US9504695B2/en active Active
-
2015
- 2015-04-21 JP JP2015086407A patent/JP5881266B2/ja not_active Expired - Fee Related
-
2016
- 2016-11-22 US US15/359,061 patent/US10335418B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CA2824317A1 (en) | 2012-07-26 |
US20170136032A1 (en) | 2017-05-18 |
ES2579990T3 (es) | 2016-08-18 |
ES2687494T3 (es) | 2018-10-25 |
US9504695B2 (en) | 2016-11-29 |
JP2014503560A (ja) | 2014-02-13 |
CA2824317C (en) | 2014-12-16 |
US10335418B2 (en) | 2019-07-02 |
US9089579B2 (en) | 2015-07-28 |
EP2665481B1 (en) | 2016-03-30 |
EP2665481A4 (en) | 2014-08-06 |
JP2015155440A (ja) | 2015-08-27 |
WO2012099942A2 (en) | 2012-07-26 |
HK1190936A1 (zh) | 2014-07-18 |
EP3378480A1 (en) | 2018-09-26 |
CA2866067A1 (en) | 2012-07-26 |
EP2982373B1 (en) | 2018-06-13 |
JP5881266B2 (ja) | 2016-03-09 |
CA2866067C (en) | 2015-04-21 |
US20150025150A1 (en) | 2015-01-22 |
EP2665481A2 (en) | 2013-11-27 |
ES2579990T8 (es) | 2016-08-26 |
JP5778781B2 (ja) | 2015-09-16 |
US20140045933A1 (en) | 2014-02-13 |
EP2982373A1 (en) | 2016-02-10 |
WO2012099942A3 (en) | 2013-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1220912A1 (zh) | 減少身體脂肪的方法和成份 | |
ZA201403661B (en) | Methods and compositions for reducing body fat and adipocytes | |
HK1201475A1 (zh) | 治療疼痛的方法和組合物 | |
EP2675471A4 (en) | HSA-RELATED COMPOSITIONS AND USE PROCESSES | |
EP2684167A4 (en) | COMPOSITIONS AND METHODS USEFUL IN THE TREATMENT OF DISEASES | |
EP2771030A4 (en) | COMPOSITIONS AND METHOD FOR THE TREATMENT OF PROTEINOPATHIES | |
IL230237B (en) | Fat Cell Compounds and Methods | |
IL238274A0 (en) | Methods and preparations for local increase of body fat | |
EP2701742A4 (en) | COMPOSITIONS AND METHOD FOR TREATING AUTOIMMUNE DISEASES | |
EP2680837A4 (en) | COMPOSITIONS AND METHODS COMPRISING C16: 1N7-PALMITOLATE | |
ZA201307187B (en) | Synergistic compositions and methods | |
HK1200345A1 (zh) | 用於表皮剝脫的組合物及其用途 | |
GB201122195D0 (en) | Composition and method | |
EP2544655A4 (en) | COMPOSITIONS AND METHODS FOR TREATING SKIN | |
EP2766009A4 (en) | METHOD AND COMPOSITIONS FOR SKIN TREATMENT | |
IL227924B (en) | Preparations and methods of use for determining a4he | |
EP2806894A4 (en) | METHODS AND COMPOSITIONS FOR THERAPEUTICS | |
EP2931324A4 (en) | COMPOSITIONS AND METHODS FOR TISSUE REGENERATION | |
IL250307A0 (en) | Pesticide preparations and methods | |
EP2741823A4 (en) | METHOD AND COMPOSITIONS FOR IMPROVING SEED FUNCTIONALITY | |
EP2755668A4 (en) | COMPOSITIONS OF HYR1 AND TREATMENT PROCEDURES THEREWITH | |
PL2731963T3 (pl) | Kompozycje i sposoby do immunomodulacji | |
ZA201308892B (en) | Compositions and methods | |
EP2767172A4 (en) | FAT COMPOSITION | |
EP2766357A4 (en) | MESOBILIVERDINE COMPOSITIONS AND METHOD THEREFOR |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20230116 |